HC Wainwright Reaffirms "Buy" Rating for Maze Therapeutics (NASDAQ:MAZE)

Key Points

• Maze Therapeutics (NASDAQ: MAZE) has had its "buy" rating reaffirmed by HC Wainwright with a target price of $50.00, suggesting a potential upside of 112.77% based on the last closing price.
• Other analysts have set varying ratings and target prices for Maze, with figures ranging from $17.00 to $37.00, reflecting a generally positive outlook on the stock.
• The company recently reported earnings of ($0.77) EPS, beating the consensus estimate of ($0.79) by $0.02, indicating some resilience in its financial performance.

HC Wainwright reiterated their buy rating on shares of Maze Therapeutics (NASDAQ:MAZE - Free Report) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a $50.00 price objective on the stock.

Several other equities research analysts have also issued reports on the company. Wedbush initiated coverage on Maze Therapeutics in a research note on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price objective for the company. BTIG Research raised their price objective on Maze Therapeutics from $30.00 to $37.00 and gave the company a "buy" rating in a research note on Friday, September 12th. Wall Street Zen raised Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Finally, Guggenheim raised their price objective on Maze Therapeutics from $19.00 to $34.00 and gave the company a "buy" rating in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat, Maze Therapeutics presently has a consensus rating of "Buy" and an average target price of $32.67.

Maze Therapeutics Stock Performance

NASDAQ MAZE traded down $0.54 during trading on Thursday, hitting $22.94. 2,551,153 shares of the stock traded hands, compared to its average volume of 703,763. The firm has a 50-day simple moving average of $16.15 and a 200-day simple moving average of $12.67. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $25.50.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.02.

Insider Activity

In related news, Director Richard H. Scheller sold 20,744 shares of the firm's stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. TRV GP IV LLC bought a new stake in Maze Therapeutics during the 1st quarter valued at $66,874,000. Frazier Life Sciences Management L.P. raised its position in Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock valued at $56,040,000 after purchasing an additional 438,274 shares in the last quarter. ARCH Venture Management LLC bought a new stake in Maze Therapeutics during the 1st quarter valued at $45,362,000. Matrix Capital Management Company LP bought a new stake in Maze Therapeutics during the 1st quarter valued at $27,373,000. Finally, Alphabet Inc. bought a new position in shares of Maze Therapeutics in the 1st quarter worth $26,561,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.